Host-directed adjunctive therapies everolimus and CC-11050 are safe and reasonably well-tolerated in adults with pulmonary tuberculosis infection, according to results of a study published in the journal Lancet Respiratory Medicine. In addition, the 2 therapies may also improve lung function recovery.
